Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

Repotrectinib has the potential to become a next-generation TKI that can be used across a broad range of NTRK fusion-positive solid tumors in both settings. In June 2024, AUGTYRO (repotrectinib ...

TSO Comprehensive is FDA approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions that may benefit ...

BMS claims to have scored again with the latest indication, as Augtyro becomes the only FDA-approved treatment option for NTRK-positive solid tumours with supporting data in patients who have and ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid tumours, shortly after clearing a rival drug from Bayer for a ...

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its new generation pan-TRK inhibitor zurletrectinib ...

A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

BEIJING, April 16, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced ...

In the registrational trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy with a good safety profile. In the registrational trial for ...

In February 2025, China’s NMPA granted priority review to repotrectinib for the treatment of adult patients with advanced solid tumors that have an NTRK gene fusion. In June 2024, AUGTYRO ...